Ignite Creation Date:
2025-12-25 @ 1:39 AM
Ignite Modification Date:
2025-12-26 @ 1:41 AM
Study NCT ID:
NCT04732494
Status:
COMPLETED
Last Update Posted:
2025-01-31
First Post:
2021-01-25
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Sponsor:
BeiGene
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-03-31
Start Date Type:
ACTUAL
Primary Completion Date:
2023-02-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-12-26
Completion Date Type:
ACTUAL
First Submit Date:
2021-01-25
First Submit QC Date:
None
Study First Post Date:
2021-02-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-12-23
Results First Submit QC Date:
None
Results First Post Date:
2025-01-31
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-12-23
Last Update Post Date:
2025-01-31
Last Update Post Date Type:
ACTUAL